ReviewPharmacoEconomics - open2020

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Angela Stainthorpe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.